hesperidin, diosmin | Detralex tablets 1000 mg 30 pcs.
Special Price
$36.80
Regular Price
$49.00
In stock
SKU
BID539588
Pharmacological action
Detralex has venotonic and angioprotective properties. The drug reduces the extensibility of veins and venous congestion, reduces the permeability of capillaries and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to venous hemodynamics.
The statistically significant dose-dependent effect of Detralex was demonstrated for the following venous plethysmographic parameters: venous capacity, venous extensibility, time of venous emptying.
The optimal dose-response ratio is observed when taken at a dose of 1000 mg per day.
Detralex increases venous tone: venous occlusion plethysmography has been shown to decrease venous emptying time.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex p using venous occlusal plethysmography, a decrease in venous emptying time was shown.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex p using venous occlusal plethysmography, a decrease in venous emptying time was shown.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex pIn the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.
Detralex has venotonic and angioprotective properties. The drug reduces the extensibility of veins and venous congestion, reduces the permeability of capillaries and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to venous hemodynamics.
The statistically significant dose-dependent effect of Detralex was demonstrated for the following venous plethysmographic parameters: venous capacity, venous extensibility, time of venous emptying.
The optimal dose-response ratio is observed when taken at a dose of 1000 mg per day.
Detralex increases venous tone: venous occlusion plethysmography has been shown to decrease venous emptying time.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex p using venous occlusal plethysmography, a decrease in venous emptying time was shown.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex p using venous occlusal plethysmography, a decrease in venous emptying time was shown.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex pIn the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.
Pharmacological action
Detralex has venotonic and angioprotective properties. The drug reduces the extensibility of veins and venous congestion, reduces the permeability of capillaries and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to venous hemodynamics.
The statistically significant dose-dependent effect of Detralex was demonstrated for the following venous plethysmographic parameters: venous capacity, venous extensibility, time of venous emptying.
The optimal dose-response ratio is observed when taken at a dose of 1000 mg per day.
Detralex increases venous tone: venous occlusion plethysmography has been shown to decrease venous emptying time.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex p using venous occlusal plethysmography, a decrease in venous emptying time was shown.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex p using venous occlusal plethysmography, a decrease in venous emptying time was shown.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex pIn the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.
Indications
Detralex® is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).
Therapy for symptoms of venous-lymphatic insufficiency:
- pain
- cramps of the lower extremities
- feeling of heaviness and fullness in the legs
- tired legs.
Therapy for manifestations of venous-lymphatic insufficiency:
- edema of the lower extremities
- trophic changes in the skin and subcutaneous tissue
- venous trophic ulcers.
Symptomatic treatment of acute and chronic hemorrhoids.
Contraindications
- Hypersensitivity to the active components or excipients that make up the drug.
Not recommended for lactating women.
Pregnancy and lactation
Animal experiments have not revealed teratogenic effects.
To date, there have been no reports of adverse effects when using the drug in pregnant women.
Due to a lack of data on the allocation of the drug to breast milk, lactation women is not recommended.
Reproductive toxicity studies have not shown an effect on reproductive function in rats of either sex.
Special instructions
Before starting to use DetralexВ®, the patient is advised to consult a doctor.
In case of exacerbation of hemorrhoids, the administration of DetralexВ® does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the time specified in the dosage regimen. In the event that the symptoms do not disappear after the recommended course of therapy, a proctologist should be examined who will select further therapy.
In the presence of impaired venous circulation, the maximum treatment effect is ensured by a combination of therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, prolonged stay on the legs, and it is recommended to reduce excess body weight. Hiking and in some cases, wearing special stockings improves blood circulation.
The patient should consult a doctor immediately if the condition worsens or no improvement occurs during treatment.
Effect on the ability to drive vehicles and control mechanisms
The drug does not affect the ability to drive vehicles and perform work requiring a high speed of mental and physical reactions.
Composition of
1 tablet contains purified micronized flavonoid fraction 1000 mg, including:
diosmin 900 mg (90%) 100 mg dondecide %)
Dosage and administration of
The drug is administered orally.
The recommended dose for venous-lymphatic insufficiency is 1 tablet / day, preferably in the morning, during meals.
Risk on tablet is intended solely for division to facilitate swallowing.
The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.
The recommended dose for acute hemorrhoids is 3 tab. / day (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets / day (1 tablet in the morning and evening) for the next 3 days.
The recommended dose for chronic hemorrhoids is 1 tablet / day.
Overdose
Cases of overdose are not described.
In case of an overdose of the drug, the patient should immediately seek medical help.
Storage conditions
The drug should be stored out of the reach of children at a temperature not exceeding 30 РC. Special storage conditions are not required.
Expiration
3 years
Deystvuyuschee substances
hesperidin, diosmin
Terms and conditions
without prescription
dosage form
Indications
Hemorroy, varicose veins, trophic yazv
Serre vie / serdix, Russia
Detralex has venotonic and angioprotective properties. The drug reduces the extensibility of veins and venous congestion, reduces the permeability of capillaries and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to venous hemodynamics.
The statistically significant dose-dependent effect of Detralex was demonstrated for the following venous plethysmographic parameters: venous capacity, venous extensibility, time of venous emptying.
The optimal dose-response ratio is observed when taken at a dose of 1000 mg per day.
Detralex increases venous tone: venous occlusion plethysmography has been shown to decrease venous emptying time.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex p using venous occlusal plethysmography, a decrease in venous emptying time was shown.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex p using venous occlusal plethysmography, a decrease in venous emptying time was shown.
In patients with signs of severe microcirculation disturbance, Detralex therapy (statistically significant compared with placebo) shows an increase in capillary resistance, evaluated by angiostereometry.
Proven therapeutic efficacy of Detralex pIn the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.
Indications
Detralex® is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).
Therapy for symptoms of venous-lymphatic insufficiency:
- pain
- cramps of the lower extremities
- feeling of heaviness and fullness in the legs
- tired legs.
Therapy for manifestations of venous-lymphatic insufficiency:
- edema of the lower extremities
- trophic changes in the skin and subcutaneous tissue
- venous trophic ulcers.
Symptomatic treatment of acute and chronic hemorrhoids.
Contraindications
- Hypersensitivity to the active components or excipients that make up the drug.
Not recommended for lactating women.
Pregnancy and lactation
Animal experiments have not revealed teratogenic effects.
To date, there have been no reports of adverse effects when using the drug in pregnant women.
Due to a lack of data on the allocation of the drug to breast milk, lactation women is not recommended.
Reproductive toxicity studies have not shown an effect on reproductive function in rats of either sex.
Special instructions
Before starting to use DetralexВ®, the patient is advised to consult a doctor.
In case of exacerbation of hemorrhoids, the administration of DetralexВ® does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the time specified in the dosage regimen. In the event that the symptoms do not disappear after the recommended course of therapy, a proctologist should be examined who will select further therapy.
In the presence of impaired venous circulation, the maximum treatment effect is ensured by a combination of therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, prolonged stay on the legs, and it is recommended to reduce excess body weight. Hiking and in some cases, wearing special stockings improves blood circulation.
The patient should consult a doctor immediately if the condition worsens or no improvement occurs during treatment.
Effect on the ability to drive vehicles and control mechanisms
The drug does not affect the ability to drive vehicles and perform work requiring a high speed of mental and physical reactions.
Composition of
1 tablet contains purified micronized flavonoid fraction 1000 mg, including:
diosmin 900 mg (90%) 100 mg dondecide %)
Dosage and administration of
The drug is administered orally.
The recommended dose for venous-lymphatic insufficiency is 1 tablet / day, preferably in the morning, during meals.
Risk on tablet is intended solely for division to facilitate swallowing.
The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.
The recommended dose for acute hemorrhoids is 3 tab. / day (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets / day (1 tablet in the morning and evening) for the next 3 days.
The recommended dose for chronic hemorrhoids is 1 tablet / day.
Overdose
Cases of overdose are not described.
In case of an overdose of the drug, the patient should immediately seek medical help.
Storage conditions
The drug should be stored out of the reach of children at a temperature not exceeding 30 РC. Special storage conditions are not required.
Expiration
3 years
Deystvuyuschee substances
hesperidin, diosmin
Terms and conditions
without prescription
dosage form
Indications
Hemorroy, varicose veins, trophic yazv
Serre vie / serdix, Russia
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review